KAM
UTHR icon

Kazazian Asset Management’s United Therapeutics UTHR Stock Holding History

Kazazian Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,506
Closed -$320K – 86
2018
Q3 		$320K Hold
2,506
– – 0.3% 63
2018
Q2 		$284K Buy
+2,506
New +$275K 0.26% 73

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kazazian Asset Management's UTHR Position: Q4 2018 in Review

Kazazian Asset Management sold out of United Therapeutics (UTHR) in Q4 2018, closing a stake of 2,506 shares — an estimated $320K sold.

Kazazian Asset Management first reported a position in UTHR in Q2 2018 and held it in 2 quarters. The position peaked at $320K in Q3 2018. 360 funds tracked by Wall St. Rank hold UTHR as of Q4 2018.

  • Kazazian Asset Management reported no remaining United Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 2,506 United Therapeutics shares in Q4 2018, an estimated $320K.
  • Kazazian Asset Management first reported a position in United Therapeutics in Q2 2018 and held it in 2 quarters.
  • Kazazian Asset Management's United Therapeutics position peaked at $320K in Q3 2018.
  • 360 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.